1. Final results of a phase 2, open‐label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome. Issue 13 (16th April 2018) Authors: Assi, Rita; Kantarjian, Hagop M.; Kadia, Tapan M.; Pemmaraju, Naveen; Jabbour, Elias; Jain, Nitin; Daver, Naval; Estrov, Zeev; Uehara, Taisuke; Owa, Takashi; Cortes, Jorge E.; Borthakur, Gautam Journal: Cancer Issue: Volume 124:Issue 13(2018) Page Start: 2758 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Issue 5 (May 2018) Authors: Italiano, Antoine; Soria, Jean-Charles; Toulmonde, Maud; Michot, Jean-Marie; Lucchesi, Carlo; Varga, Andrea; Coindre, Jean-Michel; Blakemore, Stephen J; Clawson, Alicia; Suttle, Benjamin; McDonald, Alice A; Woodruff, Mark; Ribich, Scott; Hedrick, Eric; Keilhack, Heike; Thomson, Blythe; Owa, Takas... Journal: Lancet oncology Issue: Volume 19:Issue 5(2018) Page Start: 649 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Β-Catenin/CBP inhibition alters epidermal growth factor receptor fucosylation status in oral squamous cell carcinoma. (23rd March 2020) Authors: Chandler, Kevin Brown; Alamoud, Khalid A.; Stahl, Vanessa L.; Nguyen, Bach-Cuc; Kartha, Vinay K.; Bais, Manish V.; Nomoto, Kenichi; Owa, Takashi; Monti, Stefano; Kukuruzinska, Maria A.; Costello, Catherine E. Journal: Molecular omics Issue: Volume 16:Number 3(2020) Page Start: 195 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗